J&J's Revamped R&D Will Release First Drug In 2004, Diabetic Likely Choice
Executive Summary
Johnson & Johnson's re-engineered research and development program will release its first product in 2004, most likely in the diabetes area, R&D Pharmaceuticals Chairman Per Peterson, MD/PhD, indicated.
You may also be interested in...
J&J Zarnestra R&D Overseen By Ortho Oncology/HIV Group, Headed By Mattes
Clinical development of Johnson & Johnson's farnesyl transferase inhibitor Zarnestra will be overseen by the company's tentatively named Ortho Oncology & Specialty Therapeutics business unit
J&J Zarnestra R&D Overseen By Ortho Oncology/HIV Group, Headed By Mattes
Clinical development of Johnson & Johnson's farnesyl transferase inhibitor Zarnestra will be overseen by the company's tentatively named Ortho Oncology & Specialty Therapeutics business unit
Alza Delivery Technologies Reduce Drug Enhancement Costs To $80 Mil.
Alza drug delivery technologies reduce the cost of developing an enhanced version of an already-marketed drug to $70 mil.-$80 mil., Alza Chairman Sam Saks, MD, said during Johnson & Johnson's business review Sept. 23